BusinessCognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus MeetingBy Nasdaq OMXMar 14, 2018, 2:33 PM UTC
BusinessCognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse RecoveryBy Nasdaq OMXNov 4, 2017, 2:45 PM UTC
BusinessCognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812By Nasdaq OMXOct 16, 2017, 12:00 PM UTC
